Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

Thrombotic thrombocytopenic purpura (TTP) is a known menace in hematology and is quite rare in practice with known triggers. Lately, in the COVID-19 pandemic, hematology has seen a new pathology amongst which TTP associated with COVID-19 messenger RNA (mRNA) vaccine is unique. We report a case of a 69-year-old male with multiple comorbidities who presented to the hospital with severe fatigue and shortness of breath. Labs were significant for thrombocytopenia, anemia, and hemolysis with schistocytes consistent with TTP with a second dose of BNT162b2 mRNA vaccine as a likely culprit been documented.

Automated summary

TTP, a rare hematologic threat, has been associated with COVID-19 mRNA vaccines during the COVID-19 pandemic, as seen in a case of a 69-year-old male with multiple comorbidities.